肿瘤突变负荷可预测慢性淋巴细胞白血病及单克隆B细胞增多症患者至首次治疗时间并超越CLL国际预后指数
研究纳入557例新诊断慢性淋巴细胞白血病(CLL)或高计数单克隆B细胞增多症(HC MBL)患者,测序59个基因。肿瘤突变负荷(TML)与至首次治疗时间(TTT)缩短独立于CLL-IPI相关,在低/中危CLL-IPI中关联更强且得到验证。
要点
- TML与TTT缩短相关,连续HR=1.27(95%CI 1.17-1.39,P=2.6×10⁻⁸),c-statistic=0.76。
- 按CLL-IPI分层,低/中危组TML与TTT关联更强,合并HR=1.54(95%CI 1.37-1.72,P=7.0×10⁻¹⁴)。
- HC MBL队列中TML亦与TTT缩短相关,HR=1.53(95%CI 1.12-2.07,P=.007),c-statistic=0.71。
核心结论
- TML是独立于CLL-IPI的TTT强预后因素,尤其在低/中危CLL-IPI中,且优于任何单个基因。
- 早期突变筛查可能改善风险分层并更好地预测TTT。
研究设计与样本
- 多阶段设计,对557例新诊断CLL或HC MBL个体(112例HC MBL/445例CLL)测序59个基因,估计TTT的风险比(HR)和95%置信区间(CI),校正CLL-IPI和性别。
主要发现
- TML在发现队列和验证队列中均与TTT缩短相关,合并连续HR=1.27(95%CI 1.17-1.39,P=2.6×10⁻⁸;c-statistic=0.76)。
- 按CLL-IPI分层,TML与TTT的关联在低/中危组更强并得到验证,合并HR=1.54(95%CI 1.37-1.72,P=7.0×10⁻¹⁴)。
- 低/中危CLL-IPI且≥2个突变基因者中80%在5年内进展至需要治疗,无突变者为24%。
- HC MBL队列中TML与TTT缩短相关,HR=1.53(95%CI 1.12-2.07,P=.007;c-statistic=0.71)。
关键数值与推荐
- TML连续变量合并HR=1.27(95%CI 1.17-1.39,P=2.6×10⁻⁸),c-statistic=0.76。
- 低/中危CLL-IPI组TML合并HR=1.54(95%CI 1.37-1.72,P=7.0×10⁻¹⁴)。
- HC MBL队列TML的HR=1.53(95%CI 1.12-2.07,P=.007),c-statistic=0.71。
- 低/中危CLL-IPI且≥2个突变基因者5年内需治疗比例80%,无突变者24%。
临床怎么用
- 原文结论未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Next-generation sequencing identified about 60 genes recurrently mutated in chronic lymphocytic leukemia (CLL). We examined the additive prognostic value of the total number of recurrently mutated CLL genes (i.e., tumor mutational load [TML]) or the individually mutated genes beyond the CLL international prognostic index (CLL-IPI) in newly diagnosed CLL and high-count monoclonal B-cell lymphocytosis (HC MBL). We sequenced 59 genes among 557 individuals (112 HC MBL/445 CLL) in a multi-stage design, to estimate hazard ratios (HR) and 95% confidence intervals (CI) for time-to-first treatment (TTT), adjusted for CLL-IPI and sex. TML was associated with shorter TTT in the discovery and validation cohorts, with a combined estimate of continuous HR = 1.27 (CI:1.17-1.39, P = 2.6 × 10-8 ; c-statistic = 0.76). When stratified by CLL-IPI, the association of TML with TTT was stronger and validated within low/intermediate risk (combined HR = 1.54, CI:1.37-1.72, P = 7.0 × 10-14 ). Overall, 80% of low/intermediate CLL-IPI cases with two or more mutated genes progressed to require therapy within 5 years, compared to 24% among those without mutations. TML was also associated with shorter TTT in the HC MBL cohort (HR = 1.53, CI:1.12-2.07, P = .007; c-statistic = 0.71). TML is a strong prognostic factor for TTT independent of CLL-IPI, especially among low/intermediate CLL-IPI risk, and a better predictor than any single gene. Mutational screening at early stages may improve risk stratification and better predict TTT.
引用
- Kleinstern G, O'Brien DR, Li X, et al. Tumor mutational load predicts time to first treatment in chronic lymphocytic leukemia (CLL) and monoclonal B-cell lymphocytosis beyond the CLL international prognostic index. Am J Hematol. 2020. PMID: 32279347. doi:10.1002/ajh.25831
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。